FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to plasmids encoding insulin antigens and cytokines; it can be used in medicine for the treatment or prevention of type I diabetes. An expression plasmid contains i) nucleotide sequence encoding insulin antigen, ii) nucleotide sequence encoding TGF-β, iii) nucleotide sequence encoding IL-10, and iv) nucleotide sequence encoding IL-2. The proposed plasmid also contains 2A FMDV element separating sequence encoding insulin antigen and sequence encoding TGF-β, IRES EMCV element separating sequence encoding TGF-β and sequence encoding IL-10, and 2A element separating sequence encoding IL-10 and sequence encoding IL-2.
EFFECT: invention allows for conducting tolerance-giving immunization for effective prevention and/or postponement of type I diabetes.
10 cl, 4 dwg, 11 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
| RECOMBINANT VECTORS EXPRESSING AVIAN INFLUENZA VIRUS ANTIGENS AND APPLICATIONS THEREOF | 2017 |
|
RU2761869C2 |
| VACCINES BASED ON VIRUS-LIKE PARTICLES (VLP) OF CANINE PARVOVIRUS (CPV) AND APPLICATION THEREOF | 2016 |
|
RU2710854C1 |
| CHIMERIC PROTEIN, A SYNTHETIC DNA WHICH CODES SAID PROTEIN, AN EXPRESSION VECTOR, A SYNTHETIC DNA PRODUCING STRAIN AND A METHOD OF PRODUCING PLASMID DNA | 2016 |
|
RU2736472C2 |
| VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS | 2014 |
|
RU2650860C2 |
| ANTI-CANCER VACCINES TARGETING MUC16 AND THEIR USE | 2018 |
|
RU2750689C1 |
| MUC16-TARGETING ANTICANCER VACCINES AND APPLICATION THEREOF | 2018 |
|
RU2777918C2 |
| PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
| PEPTIDE VACCINES AGAINST INTERLEUKIN-31 | 2019 |
|
RU2786441C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
